US Patent Issued to Bristol-Myers Squibb, CytomX Therapeutics on Oct. 14 for "Activatable anti-CTLA-4 antibodies and uses thereof" (California Inventors)

ALEXANDRIA, Va., Oct. 21 -- United States Patent no. 12,441,799, issued on Oct. 14, was assigned to Bristol-Myers Squibb Co. (Princeton, N.J.) and CytomX Therapeutics Inc. (South San Francisco, Calif.).

"Activatable anti-CTLA-4 antibodies and uses thereof" was invented by Kimberly Ann Tipton (South San Francisco, Calif.), James William West (South San Francisco, Calif.), Shrikant Deshpande (Fremont, Calif.) and John J. Englehardt (El Cerrito, Calif.).

According to the abstract* released by the U.S. Patent & Trademark Office: "Provided herein are activatable anti-human CTLA-4 antibodies comprising a heavy chain comprising a VH domain and a light chain comprising a masking moiety (MM), a cleavable moiety (CM), and a VL domain. Such activata...